MABIMMUNE
Mabimmune specializes in the prevention of heart attacks through early diagnosis and targeted treatment. The company was founded in 2013 and is headquartered in Schlieren, Zurich.
MABIMMUNE
Industry:
Health Care Health Diagnostics Medical
Founded:
2013-01-01
Address:
Schlieren, Zurich, Switzerland
Country:
Switzerland
Website Url:
http://www.mabimmune.com
Total Employee:
1+
Status:
Active
Total Funding:
130 K CHF
Technology used in webpage:
Domain Not Resolving
Similar Organizations
Metabolomic Diagnostics
Metabolomic Diagnostics specializes in the development of novel biomarker based diagnostic solutions for complex diseases
xRapid
xRapid is a mobile health diagnosis through disruptive solutions leveraging the use of artificial intelligence.
Founder
Investors List
Venture Kick
Venture Kick investment in Pre Seed Round - Mabimmune
Venture Kick
Venture Kick investment in Grant - Mabimmune
Venture Kick
Venture Kick investment in Grant - Mabimmune
More informations about "Mabimmune"
Mabimmune - Crunchbase Company Profile & Funding
Mabimmune specializes in the prevention of heart attacks through early diagnosis and targeted treatment. The company was founded in 2013 and is headquartered in Schlieren, Zurich. Lists Featuring This CompanySee details»
Mabimmune Diagnostics AG - VentureRadar
Website: http://www.mabimmune.com/ Develops immune agonists using Reverse Translational Medicine platform to create human monoclonal antibodies targeting tumor microenvironments, minimizing toxicity and immunogenicity risks.See details»
Mabimmune AG (merged with Neurimmune) - Venturelab
Mabimmune AG (merged with Neurimmune): Immune agonists show promising efficacy in solid tumor indications. However, dose-limiting toxicity liabilities due to on-target off-tumor binding limit their efficacy.See details»
Mabimmune - Funding, Financials, Valuation & Investors
Mabimmune specializes in the prevention of heart attacks through early diagnosis and targeted treatment.See details»
Mabimmune AG (merged with Neurimmune) - Venture Kick
Mabimmune AG (merged with Neurimmune): Immune agonists show promising efficacy in solid tumor indications. However, dose-limiting toxicity liabilities due to on-target off-tumor binding limit their efficacy. Mabimmune’s Reverse Translational Medicine (RTM) human monoclonal antibodies bind neo-epitopes unique the tumor...See details»
Mabimmune Company Profile 2024: Valuation, Funding
Operator of a healthcare company intended to treat patients with solid tumors. The company's immunotherapies improve the immune system's anti-tumor response by altering the cellular infiltrate of the tumor microenvironment with specificity, enabling patients to combat cancer, particularly in combination with checkpoint inhibitors.See details»
Mabimmune AG, Schlieren, Switzerland - North Data
The aim of the society is to develop diagnostic procedures, including diagnostic imaging, as well as research, therapy and prevention of human diseases. It also aims to manufacture and distribute diagnostic and pharmaceutical products and processes and to issue licences.See details»
Mabimmune AG (merged with Neurimmune) - startup.ch
Mabimmune AG (merged with Neurimmune) Developing immune agonists with best-in-class therapeutic indices. Website: www.mabimmune.com. Headquarter: Schlieren Foundation Date: August 2010See details»
Mabimmune Therapeutics AG - Drug pipelines, Patents, Clinical …
Explore Mabimmune Therapeutics AG with its drug pipeline, therapeutic area, technology platform, .See details»
Mabimmune - Tech Stack, Apps, Patents & Trademarks - Crunchbase
Mabimmune specializes in the prevention of heart attacks through early diagnosis and targeted treatment.See details»
Mabimmune Therapeutics AG - VentureRadar
Mabimmune aims to prevent myocardial infarction and stroke through early diagnosis and targeted treatment.See details»
Mabimmune Diagnostics AG - life-sciences-europe.com
Jan 1, 2011 · Upcoming Events. Bits & Pretzels 2024 Founders Festival München (Munich) Fierce Biotech Summit 2024 Boston; Chardan Genetic Medicines Conference 2024 New YorkSee details»
Mabimmune AG (merged with Neurimmune) - top100startup.ch
Jan 5, 2016 · Mabimmune AG (merged with Neurimmune): Immune agonists show promising efficacy in solid tumor indications. However, dose-limiting toxicity liabilities due to on-target off-tumor binding limit their efficacy. Mabimmune’s Reverse Translational Medicine (RTM) human monoclonal antibodies bind neo-epitopes unique the tumor...See details»
Four new CTI Startup Label Companies - startupticker.ch
Jun 24, 2016 · Four new startups with a common goal of improving human health have been bestowed with the CTI Label. These include Mabimmune Diagnostics, noonee, Relief Therapeutics and Topadur Pharma.See details»
mabimmune - Patents - HealthTech Alpha
Mabimmune specializes in the prevention of heart attacks through early diagnosis and targeted treatment.See details»
Chad Brokopp - Crunchbase Person Profile
Chad Brokopp was the Founding CEO and CSO in Mabimmune. He attended the University of Zurich.See details»
MedImmune to create stand-alone company for early-stage …
Feb 28, 2018 · AstraZeneca today announced that its global biologics research and development arm, MedImmune, is spinning out six molecules from its early-stage inflammation and autoimmunity programmes into an independent biotech company, Viela Bio.See details»
Mabimmune AG (merged with Neurimmune) - Venture Kick
Mabimmune AG (merged with Neurimmune): Immune agonists show promising efficacy in solid tumor indications. However, dose-limiting toxicity liabilities due to on-target off-tumor binding limit their efficacy. Mabimmune’s Reverse Translational Medicine (RTM) human monoclonal antibodies bind neo-epitopes unique the tumor...See details»
Bahija Jallal - Nature
Mar 8, 2019 · Bahija Jallal knows biologics, having spent the past 11 years working in and overseeing R&D at AstraZeneca’s biologics organization MedImmune. So when the opportunity came along to steward the...See details»